First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    ADARx Pharmaceuticals, Inc.

    ADRX · 7 developments mapped · last assessed 2026-09-25

    Market Ontology has mapped 7 macro, policy, and market developments to ADARx Pharmaceuticals, Inc. since 2026-09-25. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for ADRX yet, so no modelled value is shown. The ADRX valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run ADRX on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for ADRX. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share

      Direct market entry and capital infusion. IPO pricing and initial trading performance.

      · Moves initial market capitalization, liquidity premium, cost of equity

    • Open question

      ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq

      Direct market debut and initial trading dynamics; investor sentiment following IPO pricing and first day performance.

      · Moves initial market capitalization, investor perception of growth prospects

    What changed, by assumption

    Initial market capitalization
    • 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
    • 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
    Initial public offering price
    • 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share
    Market capitalization
    • 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
    Probability of success for clinical trials
    • 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share
    Cash runway
    • 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per shareBullishintraday0.90
    2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaqwatchintraday0.90
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Sharemixedintraday0.90
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per ShareBullish1-3m0.80
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17mixedintraday0.90
    2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per sharemixed1-5y0.90
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/ShareBullish1-5d0.90